Meningitis Organisations Worldwide Call on Asia Pacific Governments to Protect Children from Deadly Pneumococcal Disease

PERTH--13 Jun--Medianet International-AsiaNet/InfoQuest


Data presented this week at the 6th International Symposium for Pneumococci and Pneumococcal Diseases (ISPPD-6) confirms that a universal pneumococcal vaccination programme would reduce the incidence of pneumococcal disease (PD) infection and save the lives of children.

Pneumococcal disease is the number one vaccine-preventable cause of death in children younger than 5 years of age.[1]

For the first time a significant collection of data about the health and economic benefits of the PD vaccination is available to Asia Pacific governments and health authorities, supporting the call for childhood vaccination programmes in all countries.

President of the Confederation of Meningitis Organisations (COMO), Bruce Langoulant said, "With such powerful and persuasive data now available, I urge governments across the Asia Pacific to act swiftly and do everything they can to include a universal pneumococcal vaccination programme in their national immunisation schedule."

"By vaccinating our children against pneumococcal disease we have the ability to help protect not just children but the broader community and in particular parents and grandparents.

One paper presented at the symposium assessed the disease burden in children younger than five in South East Asia. It compared the number of cases of PD in the Western Pacific to this population and identified an alarming rate of vaccine preventable PD in South East Asia.

Currently, Pneumococcal Conjugate Vaccine (PCV-7, Prevenar?), is the only vaccine to prevent invasive pneumococcal disease in infants and children younger than 24 months. Australia has seen a dramatic reduction since it was introduced in January 2005 and New Zealand has included PCV-7 as part of their national immunisation programme. The focus is now on the other countries across

Asia Pacific.

"The Hong Kong Government has made significant progress towards achieving success. COMO congratulates them for taking the steps necessary towards the inclusion of the pneumococcal vaccine on their National Immunisation Programme. Let's hope they are the first of many other Asia Pacific countries to do so," said Langoulant.
"Now is the time for all health authorities to recognise the importance of protecting infants and young children against pneumococcal disease," said Langoulant.

Linda Gibbs

COMO Officer

Ph: +61 8 9489 7791

E: [email protected]

[1] Centers for Disease Control and Prevention. Vaccine preventable deaths and

the Global Immunization Vision and Strategy 2006-2015. MMWR.
2006;55(No.18):511-515. Available at:
http://www.cdc.gov/mmwr/PDF/wk/mm5518.pdf. Accessed August 7, 2007.

About COMO

The Confederation of Meningitis Organisations (COMO) was founded in September 2004, at the close of the first World Conference of Meningitis Organisations (WCMO). Attended by 43 delegates representing 20 meningitis and children's health organisations from 14 countries, the WCMO allowed attendees to learn and share best practices about education, awareness and support programs.

Encouraged by the information shared at the meeting, 20 meeting delegates formed COMO in order to help support the fight against meningitis globally by emphasizing the global burden of the disease and supporting the establishment of new meningitis and children's health organisations.

The Confederation of Meningitis Organisations' mission is to assist member organisations to be sustainable, identifiable and influential sources for information and support services for those people affected by meningitis in their regions and united in their endeavours globally through their membership of COMO, which is committed to the elimination of meningitis and septicaemia.

SOURCE: Confederation of Meningitis Organisations (COMO)

--Distributed by AsiaNet ( www.asianetnews.net )--


ข่าวPneumococcal Disease+Meningitisวันนี้

สมาพันธ์องค์การโรคเยื่อหุ้มสมองอักเสบขานรับนโยบายใหม่ของรัฐบาลฮ่องกง

บรูซ แลงกูแลนท์ ประธานสมาพันธ์องค์การโรคเยื่อหุ้มสมองอักเสบ (Confederation of Meningitis Organisations: CoMO) แสดงความชื่นชมการตัดสินใจของรัฐบาลฮ่องกงที่ให้มีการเพิ่มวัคซีนชนิดใหม่เข้าไปในโครงการฉีดวัคซีนสำหรับเด็ก โดยตั้งแต่นี้เป็นต้นไปเด็กๆ ในฮ่องกงที่เกิดหลังวันที่ 1 กันยายน พ.ศ.2550 จะได้รับวัคซีนป้องกันโรคที่เกิดจากการติดเชื้อนิวโมคอคคัส 7 ชนิด ซึ่งจะช่วยป้องกันเด็กๆ จากโรคไอพีดี (Invasive Pneumococcal Disease: IPD) “การเพิ่มวัคซีนใหม่เข้าไปในโครงการฉีดวัคซีนสำหรับเด็กถือเป็น

The Confederation of Meningitis Organisations (CoMO) Applauds the Actions of the Government of Hong Kong!

Bruce Langoulant, President of the Confederation of Meningitis Organisations (CoMO), applauds the Government of Hong Kong on the inclusion of a new vaccine to the Childhood Immunisation Program ...

Meningitis Organisations Worldwide Call on Asia Pacific Governments to Protect Children from Deadly Pneumococcal Disease

Data presented this week at the 6th International Symposium for Pneumococci and Pneumococcal Diseases (ISPPD-6) confirms that a universal pneumococcal vaccination programme would...

Thai Ministry of Public Health and WHO Host Meeting of Leading Researchers to Highlight Burden of Meningitis and Pneumonia

* Hib and Pneumococcal Disease Two Major Causes of Life-Threatening Meningitis and Pneumonia in South Asian Children * Every year the deadly diseases meningitis and pneumonia...

โรคไอพีดี หรือ IPD (Invasive Pneumococcal... โรคปอดติดเชื้อ IPD ภัยร้ายใกล้ตัวลูกน้อย — โรคไอพีดี หรือ IPD (Invasive Pneumococcal Disease) คือโรคติดเชื้อแบคทีเรียนิวโมคอคคัสชนิดรุนแรง ได้แก่ การติด...

ไอพีดี! ไม่ได้คุกคามแค่เด็ก ผู้สูงอายุก็ตกอยู่ในกลุ่มเสี่ยงโรคติดเชื้อรุนแรงเช่นกัน

คนส่วนใหญ่เข้าใจว่า โรคไอพีดี (Invasive Pneumococcal Disease : IPD) เป็นโรคที่มีความเสี่ยงต่อเด็กเท่านั้น ในความเป็นจริงผู้สูงอายุก็อยู่ในกลุ่มเสี่ยงด้วยเช่นกัน ผู้สูงอายุเป็นผู้ที่มีสุขภาพเปราะบาง เสี่ยงต่อการ...

Wyeth's Prevenar 13* Receives First Approval

-Chile Grants First Approval of Prevenar 13 for the Prevention of Pneumococcal Disease in Infants and Children- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that the Chilean Ministry of Health, MINSAL (Ministerio de Salud), has...

New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease

New data from Phase 3 European clinical trials reinforce that Wyeth's (NYSE: WYE) investigational pneumococcal vaccine, Prevenar 13* (Pneumococcal...